Exagen (XGN)
(Delayed Data from NSDQ)
$1.41 USD
0.00 (0.15%)
Updated Apr 26, 2024 03:50 PM ET
3-Hold of 5 3
C Value A Growth F Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
XGN 1.41 0.00(0.15%)
Will XGN be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for XGN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for XGN
Exagen Inc. (XGN) Reports Q4 Loss, Tops Revenue Estimates
Cresco Labs Inc. (CRLBF) Q4 Earnings and Revenues Surpass Estimates
XGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zynex Inc. (ZYXI) Q4 Earnings and Revenues Miss Estimates
Despite Fast-paced Momentum, Exagen Inc. (XGN) Is Still a Bargain Stock
Exagen Inc. (XGN) Reports Q2 Loss, Tops Revenue Estimates
Other News for XGN
Exagen Inc. Announces Changes to the Board of Directors
Exagen Inc Board Reshuffle and New Class I Director Appointment
Exagen to reduce size of board to seven from nine
Wall Street Analysts Are Bullish on Top Healthcare Picks
Buy Rating Affirmed for Exagen on Strong Financials and Strategic Growth Initiatives